Nada Hindiyeh
Neurology · San Francisco, CANPI 1831320720
Payments from drug & device makers
Across 565 payments — averaging $1205.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$222K
- Lilly USA, LLC$105K
- AbbVie$95K
- Lundbeck LLC$68K
- H. Lundbeck A S$41K
- Impel Pharmaceuticals Inc.$37K
- plus $113K from 8 others
Across 2 payments — averaging $949.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
What the payments were for
- Consulting fees$140,25752%
- Speaking & faculty fees$67,83725%
- Travel & lodging$52,71720%
- Food & beverage$6,5882%
- Education$7940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 240 | $221,941 |
| Lilly USA, LLC | 129 | $104,843 |
| AbbVie(2 entities) | 37 | $95,023 |
| Lundbeck LLC | 33 | $68,025 |
| H. Lundbeck A S | 6 | $40,809 |
| Impel Pharmaceuticals Inc. | 26 | $37,496 |
| Eli Lilly | 49 | $31,812 |
| Novartis | 14 | $27,525 |
| Pfizer | 8 | $18,087 |
| Axsome Therapeutics, Inc. | 5 | $13,342 |
| Amgen | 14 | $12,612 |
| Teva Pharmaceuticals USA, Inc. | 2 | $9,390 |
| Ipsen Biopharmaceuticals, Inc | 1 | $66 |
| Pharming Healthcare, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$680,991 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 12 | $22,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $18,087 | $22,59912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Adam BoxerSan Francisco$5.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Jonathan KatzSan Francisco$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.